For comments, suggestions
Created with Raphaël 2.1.0 01.07.2016 Filing date 02.02.2018 Validation fee payment 30.06.2018 (A1) Patent application published 12.06.2020 AGEPI application filing date 31.07.2020 (T2) Translation of the validated European patent 07.06.2025 01.07.2025 Valid until 02.07.2026 Renewal fee to be paid until 01.07.2036 Patent will expire on

Patent in force


(210)Number of the EPO application16735945
(220)Filing date of the EPO application2016.07.01
(80)EPO patent specification publication (B)EPB nr. 17/2020, 2020.04.22
(110)EPO patent number3317281
(11)Number of the documentMD 3317281 T2
(21)Number of the applicatione 2018 0479
(71)Name(s) of applicant(s), code of the countryAcerta Pharma B.V., NL;
(72)Name(s) of inventor(s), code of the countryBLATTER Fritz, CH;
INGALLINERA Tim, US;
BARF Tjeerd, NL;
ARET Edwin, NL;
KREJSA Cecile, US;
EVARTS Jerry, US;
(73)Name(s) of owner(s), code of the countryACERTA Pharma B.V., NL;
(54)Title of the inventionSolid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
(13)Kind-of-document code T2
(51)International Patent Classification C07D 487/04 (2006.01.01); A61K 31/4985 (2006.01.01); A61P 35/00 (2006.01.01)
(19)CountryNL
(41)Date of publication of the application2018.06.30
(49)Date of publication of the translation of the validated European patent specification2020.07.31
(30)Priority201562188468 P, 2015.07.02, US; 201562271708 P, 2015.12.28, US
(74)Patent attorney(Procedură) CORCODEL Angela, Bd. Ştefan cel Mare nr. 134, Chişinău, Republica Moldova
(86)International applicationPCT/IB2016/053988, 2016.07.01
(87)International publicationWO 2017/002095, 2017.01.05
Up
/Inventions/details/3317281